This is a demo store. No orders will be fulfilled.

INSERM patent anti-DC-SIGN (anti-DC-SIGN) - Primary antibody, specific to CD209, Human IgG1

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Human
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
In stock
Item Number
Ab209899
Grouped product items
SKU Size
Availability
Price Qty
Ab209899-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$109.90
Ab209899-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$509.90
Ab209899-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,399.90
Ab209899-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,299.90

Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name INSERM patent anti-DC-SIGN (anti-DC-SIGN) - Primary antibody, specific to CD209, Human IgG1
Synonyms C type lectin domain family 4 member L antibody | C-type lectin domain family 4 member L antibody | CD 209 antibody | CD209 antibody | CD209 antigen antibody | CD209 antigen-like protein A antibody | CD209 molecule antibody | CD209_HUMAN antibody | Cd209a
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Biochemical and Physiological Mechanisms Pathogen-recognition receptor expressed on the surface of immature dendritic cells (DCs) and involved in initiation of primary immune response. Thought to mediate the endocytosis of pathogens which are subsequently degraded in lysosomal compartments. The
Host species Human
Specificity CD209
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Product Description

INSERM patent anti-DC-SIGN (anti-DC-SIGN) is a humanized monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients.

Product Properties

Isotype Human IgG1
Light Chain Type kappa
SDS-PAGE 150 kDa
Purification Method Protein A purified
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Associated Targets(Human)

CD209 Tchem CD209 antigen (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

INSERM patent anti-DC-SIGN (anti-DC-SIGN) (Ab209899) - ELISA
Immobilized Recombinant Human-DC- SIGN/CD209-his at 2.0 μg/mL can bind INSERM patent anti-DC-SIGN (anti-DC-SIGN) (Ab209899) with the EC₅₀ of 518.9 ng/mL.

INSERM patent anti-DC-SIGN (anti-DC-SIGN) (Ab209899) - SEC
The purity of INSERM patent anti-DC-SIGN (anti-DC-SIGN) (Ab209899) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.